Latest AMD Stories
PLANO, Texas, Jan. 3, 2012 /PRNewswire/ -- MacuCLEAR, Inc., a specialty clinical stage pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, today announced it has secured more than $1M in funds from current investors. The funds will be used to complete a pivotal, Phase 3a human efficacy trial for its lead product, MC-1101. Concurrently, MacuCLEAR has also entered into a strategic partnership with a Pacific Rim...
BOSTON, Dec. 20, 2011 /PRNewswire/ -- Credorax, a leading developer of next generation technology for the processing of online payment transactions, and a Financial Institution licensed under the EU Payment Services Directive (PSD), announced today that it has selected AMD (NYSE: AMD) Opteron(TM) processors for its proprietary NextGen ePower(TM)( )Payment Processing and Acquiring Platform. Through this collaboration, the AMD Opteron technology, which features up to 16 processor cores...
TARRYTOWN, N.Y. and BERLIN, Dec. 5, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that in an integrated analysis of two parallel Phase 3 studies (VIEW 1 and VIEW 2) in patients with the neovascular form of age-related macular degeneration (wet AMD), patients treated with EYLEA(TM) (aflibercept) Injection For Intravitreal Injection showed a sustained improvement in visual acuity at 96 weeks versus baseline. The 52-week...
SANTA CLARA, Calif., Dec. 2, 2011 /PRNewswire/ -- NextOp Software, Inc. today announced that AMD (NYSE: AMD), has signed a multi-year, multi-license agreement for worldwide deployment of NextOp's BugScope assertion synthesis product. NextOp's BugScope improves functional verification via a unified assertion-based verification methodology for AMD's simulation, formal, and emulation verification environments. BugScope's automation is intended to enable AMD designers to quickly ramp up an...
LOS ANGELES, Nov. 30, 2011 /PRNewswire-USNewswire/ -- Physicians at Good Samaritan Hospital in Los Angeles successfully implanted the FDA-approved eye telescope, a first in California. The first-of-kind telescope implant is integral to CentraSight(TM), a new patient care program for treating patients with end-stage age-related macular degeneration (AMD), the most advanced form of AMD and the leading cause of blindness in older Americans. It is the only medical/surgical option that...
TARRYTOWN, N.Y. and BERLIN, Nov. 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that they have initiated a Phase 3 clinical trial evaluating the efficacy and safety of EYLEA(TM) (aflibercept) Injection in the neovascular form of age-related macular degeneration (wet AMD) in China. The new trial, named SIGHT, will include approximately 300 patients and will be the largest retinal trial conducted in China. SIGHT is being...
VANCOUVER, British Columbia, Nov. 23, 2011 /PRNewswire-Asia/ -- Pennystocksinsiders.com (PSI) has issued insider trading reports and Equity Research for the following companies: High Plains Gas (OTC:HPGS), Legend Oil and Gas (OTC:LOGL), AMD (NYSE:AMD), Sprint Nextel (NYSE:S), EMC (NYSE:EMC) & Research In Motion (NASDAQ:RIMM). (Logo: http://photos.prnewswire.com/prnh/20110914/HK68141LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full link to your...
In the news release, Regeneron Announces FDA Approval of EYLEA(TM) (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration, issued 18-Nov-2011 by Regeneron Pharmaceuticals, Inc. over PR Newswire, the third paragraph, second sentence, should read "EYLEA offers the potential of achieving the efficacy we've come to expect from current anti-VEGF agents, but with less frequent injections and monitoring." The complete, corrected release follows: Regeneron Announces FDA...
TARRYTOWN, N.Y., Nov. 18, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA( )(aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams (mg) every four weeks (monthly) for the first 12 weeks, followed by 2 mg every eight weeks...
Maintains clearness of vision in those with wet age-related macular degeneration SILVER SPRING, Md., Nov. 18, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Eylea (aflibercept) to treat patients with wet (neovascular) age-related macular degeneration (AMD), a leading cause of vision loss and blindness in Americans ages 60 and older. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) AMD gradually destroys a person's sharp, central vision. It...
